Phase II trial of MVE-II in metastatic malignant melanoma. 1987

J Rinehart, and J LaForge, and D Gochnour, and J Neidhart

MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D011713 Pyran Copolymer Copolymer of divinyl ether and maleic anhydride that acts as an immunostimulant with antineoplastic and anti-infective properties. It is used in combination with other antineoplastic agents. Divinyl Ether Maleic Anhydride Copolymer,Maleic Anhydride Divinyl Ether,Maleic Anhydride Vinyl Ether,Vinyl Ether Maleic Anhydride Polymer,DIVEMA,MVE-2,MVE-5,NSC-46015,Copolymer, Pyran,MVE 2,MVE 5,NSC 46015,NSC46015
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1985, Cancer treatment reports,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
October 1983, American journal of clinical oncology,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1994, Investigational new drugs,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
March 1978, Cancer treatment reports,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
November 2007, Anti-cancer drugs,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1993, Investigational new drugs,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1981, Cancer treatment reports,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1985, Cancer treatment reports,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
June 1982, Cancer treatment reports,
J Rinehart, and J LaForge, and D Gochnour, and J Neidhart
January 1997, Cancer investigation,
Copied contents to your clipboard!